Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
SAN DIEGO, May 18, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference. Based on an abstract entitled "A small molecule S1P1 receptor agonist with significant efficacy in animal models of inflammatory bowel disease (IBD)," Receptos scientific personnel will discuss positive preclinical data with RPC1063 in two distinct in vivo models of IBD.
"Based on exciting data from these preclinical studies, as well as data from a recently completed Phase 1 clinical safety study, Receptos will initiate a Phase 2 clinical trial with RPC1063 in 2012 in inflammatory bowel disease," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "The acceptance of these preclinical efficacy data for presentation at DDW underscores the need for efficacious oral treatments for the therapeutic treatment of IBD and the excitement on the part of scientific and clinical investigators to explore the novel profile of RPC1063 in patients suffering from this debilitating disease."
About RPC1063 and S1P1 Agonists
RPC1063 is a novel, differentiated sphingosine 1-phosphate 1 receptor (S1P1) selective agonist exhibiting picomolar potency that is effective in rodent models of both multiple sclerosis (MS) and inflammatory bowel disease (IBD), and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy trials in 2012. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In autoimmune disorders, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying cause of disease.
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information‐driven drug discovery, including GPCR structure determination. The company's lead program, RPC1063, is a best‐in‐class S1P1 small molecule agonist candidate for autoimmune indications. The S1P1 program is supported by the company's proprietary high resolution protein crystal structure of the S1P1 receptor. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.
Cindy McGee (investors)
SOURCE Receptos Inc.